An open-label, randomised, phase II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2019
This article has no abstract
Epistemonikos ID: c991564e6136aa42886ba3a9409689c5e15b55bb
First added on: Jan 23, 2025